role of ganciclovir in the prevention of Post-transplant lymph proliferative disease in children underwent liver transplantation

The role of ganciclovir in the prevention of Post-transplant lymph proliferative disease in children underwent liver transplantation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013120215530N2

Enrollment

203

Registered

2014-01-31

Start date

2010-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplanted organ and tissue status. Liver transplant status

Interventions

Intervention 1: Intervention group: children who underwent a liver transplant in January 2010 to the end of 2011 received prophylaxis Gansiclovir10mg/kg,Two divided doses. Intervention 2: Control gro

Treatment - Drugs

Intervention group: children who underwent a liver transplant in January 2010 to the end of 2011 received prophylaxis Gansiclovir10mg/kg,Two divided doses.

Control group:children who had undergone liver transplantation but did not receive Gansiklovir.

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age less than 18 years; performing a liver transplant Exclusion criteria: transplant before July 88 and after March 90; die within the first week after transplantation due to postoperative complications

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Prevention of Post-transplant lymph proliferative disease. Timepoint: A month later. Method of measurement: examinations.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactkaramali kasiri

Shahrekord University of Medica Sciences.

kasiri@skums.ac.ir+98 38 1222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026